FindTrial
Sign In

Study of a Polymorphism in Patients With Prostate Cancer

Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00900185
Enrollment
750
Registered
2009-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2015-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

recurrent prostate cancer, stage I prostate cancer, stage IIB prostate cancer, stage IIA prostate cancer, stage III prostate cancer, stage IV prostate cancer

Brief summary

RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA. PURPOSE: This laboratory study is looking at blood samples from patients with prostate cancer and from healthy participants to identify a polymorphism that may help in the study of prostate cancer.

Detailed description

OBJECTIVES: Primary * Determine the incidence of the D104N COL18A1 polymorphism in patients with prostate cancer. Secondary * Determine the incidence of this polymorphism in African-American patients with prostate cancer. OUTLINE: This is a retrospective, multicenter study. DNA is extracted from preexisting serum samples and polymerase chain reaction is performed to determine the genotype pattern. PROJECTED ACCRUAL: A total of 500 patients and 250 healthy participants will be accrued for this study.

Interventions

GENETICmutation analysis
GENETICpolymerase chain reaction
GENETICpolymorphism analysis

Sponsors

National Cancer Institute (NCI)
Lead SponsorNIH

Eligibility

Sex/Gender
MALE
Healthy volunteers
Yes

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of prostate cancer OR healthy participant * Patient enrolled on an IRB-approved clinical trial at the National Cancer Institute or Northwestern University, including, but not limited to, any of the following: * NCI-99-C-0052 * NCI-95-C-0178 * NCI-00-C-003 * NCI-00-C-0080 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

MeasureTime frame
Frequency of D104N COL18A1 polymorphism in patients with prostate cancer and in healthy participants—

Secondary

MeasureTime frame
Frequency of D104N COL18A1 polymorphism in African-American patients with prostate cancer and in healthy participants—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026